PK/PD Analysis Service for Stroke Drug Discovery and Development

The relationship between Pharmacokinetics (PK) and pharmacodynamics (PD) is described by PK/PD analysis, which relates drug concentration to drug action and is an alternative to traditional dose-effect analysis. Effective PK/PD analysis provides insight into the mechanism of stroke drug action and identifies PK characteristics. Integration of PK/PD in early stroke drug development can aid in compound selection and guide the creation of effective clinical development strategies.

Fig. 1. Schematic of how mechanistic PK/PD models can support drug discovery and development across the pipeline. (Grant et al., 2023)

Custom PK/PD Study Design in Stroke Drug Discovery and Development

Ace Therapeutics's core stroke drug discovery team of pharmacologists, DMPK scientists, biologists, and chemists are well versed in the animal models of stroke and study designs used in their programs and can craft PK/PD studies to help clients understand the mechanism of action of their stroke medications and select the best compounds. We aim to accelerate your preclinical stroke drug development.

Discussions with our core team address key questions and aspects of your PK/PD studies:

Selection of efficacy readouts, such as biomarkers or effective endpoints
Study design regarding dosing regimens, time points, and PK analysis
Evaluation of technologies related to PK/PD studies

PK/PD Analysis Services

Ace Therapeutics offers comprehensive PK/PD analysis services for stroke drug candidates, helping clients select promising compounds and identify potentially safe and effective dosage and delivery regimens.

Concentration-Effect Relationship Analysis

Based on our rich cell library and experimental animals, in the concentration-effect relationship analysis, Ace Therapeutics performs experiments on multiple specimens to draw concentration-effect curves and obtain rich concentration-effect relationship data.

Concentration for 50% of maximal effect (EC₅₀)
Median effective dose (ED₅₀)
Median lethal dose (LD₅₀)
Median toxic dose (TD₅₀)

Time-Effect Relationship Analysis

By setting different time points for drug administration and testing the effects of drugs in different cells or animals, Ace Therapeutics provides comprehensive analysis services of the time-effect relationship.

The time-effect relationship can be divided into 3 phases: latent phase, duration, and residual phase. Our scientists will specify the appropriate experimental protocol for your stroke study.

Structure-Activity Relationship Analysis

Ace Therapeutics provides 2-dimensional quantitative conformational analysis services and 3-dimensional quantitative conformational analysis services to facilitate the progress of your stroke drug research with comprehensive, high quality, and professional services.

2-dimensional quantitative conformational analysis services	Select the appropriate data to be tested and create the database to be tested Select the appropriate molecular structure parameters and the activity parameters to be studied from the database Select a suitable method to model the quantitative relationship between structural and activity parameters Model testing and optimization Practical application to predict the activity of new compounds
3-dimensional quantitative conformational analysis services	Performed by comparative molecular field analysis method and comparative molecular similarity method.

Ace Therapeutics can establish robust PK/PD relationships in animal models of stroke, and these data can be used to help predict expected effects in the clinic under a number of assumptions. If you are interested in our services, please do not hesitate to contact us!

Reference

Grant, J., et al. (2023, December). Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions. In Mabs (Vol. 15, No. 1, p. 2192251). Taylor & Francis.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.